Literature DB >> 7202473

Simultaneous determination of the intravenous and oral pharmacokinetic parameters of D,L-verapamil using stable isotope-labelled verapamil.

M Eichelbaum, A Somogyi, G E von Unruh, H J Dengler.   

Abstract

Following i.v. administration, the plasma concentration-time curve of verapamil could best be described by either a mono- or biexponential equation. Total plasma clearance (1.26 1/min) approached liver blood flow (1.51/min), so it can be concluded that its clearance is liver blood flow-dependent. Although absorption was almost complete after oral administration, absolute bioavailability (20%) was low, due to extensive hepatic first-pass metabolism. The approach using stable isotope-labelled and unlabelled drug permits simultaneous administration by the intravascular and extravascular routes, thus allowing determination of absolute bioavailability in a single experiment.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7202473     DOI: 10.1007/bf00568400

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  15 in total

1.  Linear pharmacokinetic equations allowing direct calculation of many needed pharmacokinetic parameters from the coefficients and exponents of polyexponential equations which have been fitted to the data.

Authors:  J G Wagner
Journal:  J Pharmacokinet Biopharm       Date:  1976-10

2.  GLC assay of verapamil in plasma: identification of fluorescent metabolites after oral drug administration.

Authors:  R G McAllister; T G Tan; D W Bourne
Journal:  J Pharm Sci       Date:  1979-05       Impact factor: 3.534

3.  Determination of verapamil in human plasma by mass fragmentography using stable isotope-labelled verapamil as internal standard.

Authors:  B Spiegelhalder; M Eichelbaum
Journal:  Arzneimittelforschung       Date:  1977

4.  Number of exponential terms describing the solution of an N-compartmental mammillary model: vanishing exponentials.

Authors:  D P Vaughan; M J Dennis
Journal:  J Pharmacokinet Biopharm       Date:  1979-10

5.  Influence of meso-caval shunt surgery on verapamil kinetics, bioavailability and response.

Authors:  M Eichelbaum; M Albrecht; G Kliems; K Schäfer; A Somogyi
Journal:  Br J Clin Pharmacol       Date:  1980-11       Impact factor: 4.335

6.  The metabolism of DL-[14C]verapamil in man.

Authors:  M Eichelbaum; M Ende; G Remberg; M Schomerus; H J Dengler
Journal:  Drug Metab Dispos       Date:  1979 May-Jun       Impact factor: 3.922

7.  Fluorometric assay of verapamil in biological fluids and tissues.

Authors:  R G McAllister; S M Howell
Journal:  J Pharm Sci       Date:  1976-03       Impact factor: 3.534

8.  Physiological disposition of verapamil in man.

Authors:  M Schomerus; B Spiegelhalder; B Stieren; M Eichelbaum
Journal:  Cardiovasc Res       Date:  1976-09       Impact factor: 10.787

9.  Pharmacokinetics of verapamil in man.

Authors:  Y Koike; K Shimamura; I Shudo; H Saito
Journal:  Res Commun Chem Pathol Pharmacol       Date:  1979-04

10.  Superiority of stable isotope techniques in the assessment of the bioavailability of drugs undergoing extensive first pass elimination. Studies of the relative bioavailability of verapamil tablets.

Authors:  M Eichelbaum; H J Dengler; A Somogyi; G E von Unruh
Journal:  Eur J Clin Pharmacol       Date:  1981-01       Impact factor: 2.953

View more
  32 in total

1.  Evaluation of the utility of a proposed method for correcting for intrasubject variability in metabolic clearance in the bioavailability assessment of theophylline.

Authors:  Y Kasuya; T Furuta; H Shibasaki; H Shimota
Journal:  J Pharmacokinet Biopharm       Date:  1991-02

2.  Spline functions in convolutional modeling of verapamil bioavailability and bioequivalence. II: study in healthy volunteers.

Authors:  J Popović; R Mitić; A Sabo; M Mikov; V Jakovljević; K Daković-Svajcer
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2006 Apr-Jun       Impact factor: 2.441

3.  Validation of the hepatic blood flow rate model for verapamil first-pass metabolism.

Authors:  Jovan Popović
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2007 Jan-Mar       Impact factor: 2.441

4.  Simultaneous study of the pharmacokinetics of intravenous and oral nicardipine using a stable isotope.

Authors:  M Guerret; G Cheymol; M Hubert; C Julien-Larose; D Lavene
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

5.  The assessment of bioavailability in the presence of nonlinear elimination.

Authors:  S D Hall; C B McAllister; G R Wilkinson
Journal:  J Pharmacokinet Biopharm       Date:  1988-06

6.  Relationship between the stereoselective negative inotropic effects of verapamil enantiomers and their binding to putative calcium channels in human heart.

Authors:  D R Ferry; H Glossmann; A J Kaumann
Journal:  Br J Pharmacol       Date:  1985-04       Impact factor: 8.739

Review 7.  Pharmacokinetic and pharmacodynamic considerations in drug therapy of cardiac emergencies.

Authors:  P Pentel; N Benowitz
Journal:  Clin Pharmacokinet       Date:  1984 Jul-Aug       Impact factor: 6.447

8.  Pharmacokinetics, bioavailability and ECG response of verapamil in patients with liver cirrhosis.

Authors:  A Somogyi; M Albrecht; G Kliems; K Schäfer; M Eichelbaum
Journal:  Br J Clin Pharmacol       Date:  1981-07       Impact factor: 4.335

9.  Pharmacokinetics of (+)-, (-)- and (+/-)-verapamil after intravenous administration.

Authors:  M Eichelbaum; G Mikus; B Vogelgesang
Journal:  Br J Clin Pharmacol       Date:  1984-04       Impact factor: 4.335

Review 10.  Clinical pharmacokinetics of verapamil, nifedipine and diltiazem.

Authors:  H Echizen; M Eichelbaum
Journal:  Clin Pharmacokinet       Date:  1986 Nov-Dec       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.